Abstract
Objective: To evaluate of life expectancy of patients with newly diagnosed multiple myeloma (MM) treated by high dose melphalan and frozen autologous peripheral blood stem cell transplantation at Hematology and Blood transfusion hospital.
Methods: From January 2012 to September 2015, 30 eligible patients with adequate cardiac, pulmonary and renal function who had undergone induction with bortezomib and dexamethasone (BD). Melphalan at 200 mg/m2 was used as a conditioning regimen. The median of the transfused the CD34+ cells was 5×106/kg.
Results: Median age was 49.1 .1±6.21 years. After a median follow-up of 26 months, the median overall and event-free survivals were 39.9±2.5 months (CI 95%, 35.1-44.9) and 28.9±3.1 months (CI 95%. 22.8-35.2), respectively. The overall survival and progressive free survival of 2 years were 83% và 59.5%, resprectively.
Conclusions: Autologous stem cell transplantation (ASCT) helps to prolong MM patient survival. Key words: multiple myeloma (MM), autologous stem cell transplantation (ASCT)
References
Bạch Quốc Khánh. (2014), Nghiên cứu hiệu quả của ghép tế bào gốc tự thân điều trị bệnh đa u tủy xương và u lymphô ác tỉnh không Hodgkin, Luận án Tiến sĩ Y học, Đại học Y Hà Nội.
Suzanne MCB Thanh Thanh và cs (2011), Nghiên cứu đặc điểm cận lâm sàng của bệnh đa u tủy tại khoa Huyết học, Bệnh viện Chợ Rẫy", Y học TP. Hồ Chí Minh, 15(4), tr. 34-42.Alyea E W. E., Schlossman R, et al (2003), "Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.", Bone Marrow Transplant, 32, pp. 1145-1151.
Bjiirkstrand B. (1995), "Autologous Stem Cell Transplantation in Multiple Myeloma: Results of the European Group for Bone Marrow Transplantation ", STEM CELLS 13 (supp 12), pp.140-146
Cavo MT. P., Patriarca Fet al (2010), "Bortezomib thalidomide and dexamehasone compared with thalidomide and dexamethasone as induction before and consolidation therapy afyter double autologous stem cell transplantation in newly diagnosed multiple myeloma: result froma rndomized phase III study.", Lancet Oncol, 379, pp.2075-208.
Chanan-Khan A G. S. (2010), "Importance of achieving a complete response inmultiple mycloma and the impact of novel agents.", J Clin Oncol 28, pp.2612-2624.
Harousseau JL A. M., Avet-Loiseau Het al. (2010), "Bortezomib plus dexamethasone is superior to vincristin plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. ", J Clin Oncol, 28, pp.46214629.
Hoering A., J. Crowley, J. D. Shaughnessy Jr, et al. (2009), " Complete remission in multiple myeloma examined as time dependent variable in terms of both onset and duration in Total Therapy protocols. ", Blood, 114, pp.1299-1305.
Kumar L C. S., Tejomurtula TV, et al (2013), "Autologous stem cell transplantation for multiple myeloma: identification of prognostic factors", Clin Lymphoma Myeloma Leuk, 13(1), pp.32-41.
Le B.-H. (2013), "Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy", Int J Hematol 97, pp.634-639
Michel Attal J. LL. H. e. a. (1996), "A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma", The New England Journal of Medicine, 335(2), pp.56-63.
Moreau P., et al (2011), "Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies", J Clin Oncol, 29(14), pp. 1898-906.
| Published | 31-10-2017 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 46 (2017) | |
| Section | Original article | |
| DOI | ||
| Keywords | Đa u tủy, ghép tế bào gốc tự thân multiple myeloma (MM), autologous stem cell transplantation (ASCT) |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital